AFM-30a hydrochloride is a potent protein arginine deiminase 2 (PAD2) inhibitor and has excellent PAD2-selectivity. AFM-30a hydrochloride binds to PAD2 with an EC50 value of 9.5 μM. AFM-30a hydrochloride also inhibits H3 citrullination with an EC50 value of 0.4 μM. AFM-30a hydrochloride can be used for the research of certain cancers and a variety of autoimmune diseases including rheumatoid arthritis (RA), multiple sclerosis, lupus, and ulcerative colitis[1].
AFM-30a hydrochloride (compound 30a; 25 μM) has good potency to enter HEK293T/PAD2 cells and covalent modify PAD2 with an EC50 of 9.5 μM[1].
AFM-30a hydrochloride shows good ability to inhibit H3 citrullination with an EC50 of 0.4 μM[1].
Cell Viability Assay[1]
| Cell Line: | HEK293T/PAD2 cells |
| Concentration: | Various concentrations |
| Incubation Time: | 24 h |
| Result: | Exhibited low cytotoxicity for cells. |
AFM-30a hydrochloride suppresses NLRP3 signaling and decreases airway remodeling in PAD2-/-transgenic mice[2].
















